KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Average (2016 - 2025)

Historic Equity Average for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $242.2 million.

  • Alnylam Pharmaceuticals' Equity Average rose 155426.64% to $242.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.2 million, marking a year-over-year increase of 155426.64%. This contributed to the annual value of -$76.8 million for FY2024, which is 5946.97% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Equity Average stood at $242.2 million, which was up 155426.64% from $183.0 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Equity Average high stood at $971.2 million for Q1 2021, and its period low was -$333.7 million during Q2 2023.
  • For the 5-year period, Alnylam Pharmaceuticals' Equity Average averaged around $173.1 million, with its median value being $54.2 million (2022).
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Equity Average plummeted by 62950.78% in 2023, and later skyrocketed by 155426.64% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Equity Average (Quarter) stood at $672.0 million in 2021, then crashed by 116.8% to -$112.9 million in 2022, then tumbled by 71.13% to -$193.3 million in 2023, then surged by 125.73% to $49.7 million in 2024, then surged by 387.2% to $242.2 million in 2025.
  • Its Equity Average stands at $242.2 million for Q3 2025, versus $183.0 million for Q2 2025 and $91.3 million for Q1 2025.